Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy
- PMID: 17047197
- DOI: 10.1093/jnci/djj397
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy
Abstract
Background: The use of oncolytic adenoviruses as cancer gene therapy is limited by their uneven penetration and distribution in tumors. We investigated whether the expression of the cell matrix-degradative protein relaxin by adenovirus could improve adenovirus distribution and penetration in tumors.
Methods: We generated relaxin-expressing, replication-incompetent (dl-lacZ-RLX) and -competent (Ad-deltaE1B-RLX) adenoviruses by inserting a relaxin gene into the E3 adenoviral region. Controls were parental adenoviruses (dl-lacZ and Ad-deltaE1B) and phosphate-buffered saline (PBS) (vehicle). Replication-incompetent viruses, which do not lyse cells, were used to assess transduction efficiency. Viral spread in tumor spheroids, made by dissecting tumor tissue into homogeneous fragments, was assessed by reporter gene (i.e., lacZ) expression. Tumor growth inhibition was assessed by injecting adenoviruses into xenograft tumors in athymic mice (n = 8 or 9). Overall survival was assessed by the Kaplan-Meier method. Extracellular matrix was examined with Masson's trichrome staining. Therapeutic efficacy was evaluated by assessing spontaneous pulmonary metastasis in the B16BL6 melanoma mouse model and growth inhibition of orthotopically implanted hepatoma (n = 4-6). All statistical tests were two-sided.
Results: In tumor spheroids and established solid tumors in vivo, transduction with dl-lacZ-RLX, compared with parental virus or vehicle, elicited higher transduction efficiency and viral spread throughout the tumor mass. Infection with Ad-deltaE1B-RLX, compared with parental virus, elicited greater viral persistence and spread, leading to increased survival (e.g., 100%, 95% confidence interval [CI] = 63.1% to 100%, for C33A tumor-bearing mice treated with Ad-deltaE1B-RLX, and 50%, 95% CI = 15.7% to 84.3%, for C33A tumor-bearing mice treated with Ad-deltaE1B). Infection with Ad-deltaE1B-RLX substantially decreased the collagen content of tumor tissue but not of adjacent normal tissue, compared with noninfected tissues. Intratumoral injection of Ad-deltaE1B-RLX inhibited the formation of lung metastases in mice (PBS = 268 mg of metastatic tumor per mouse and Ad-deltaE1B-RLX = 10 mg; difference = 258 mg, 95% CI = 94 to 426; P = .003, Mann-Whitney test). Systemic treatment with Ad-deltaE1B-RLX completely inhibited the growth of Hep1 hepatocellular carcinomas (PBS = 20.2 mg of tumor per mouse and Ad-deltaE1B-RLX = 0 mg; difference = 20.2 mg, 95% CI = 3.7 to 36.7; P = .004, Mann-Whitney test).
Conclusion: Extracellular matrix degradation by relaxin expressed by adenoviruses increased viral distribution and tumor penetration, inhibited tumor growth and metastasis, and increased survival of mice.
Similar articles
-
Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy.Gene Ther. 2010 Feb;17(2):190-201. doi: 10.1038/gt.2009.142. Epub 2009 Nov 12. Gene Ther. 2010. PMID: 19907500
-
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.Cancer Res. 2007 May 1;67(9):4399-407. doi: 10.1158/0008-5472.CAN-06-4260. Cancer Res. 2007. PMID: 17483354
-
Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.Clin Cancer Res. 2002 Apr;8(4):1258-70. Clin Cancer Res. 2002. PMID: 11948141
-
Therapy of cancer by cytokines mediated by gene therapy approach.Cell Res. 2006 Feb;16(2):182-8. doi: 10.1038/sj.cr.7310025. Cell Res. 2006. PMID: 16474432 Review.
-
Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement.Ann Biomed Eng. 2006 Jan;34(1):114-27. doi: 10.1007/s10439-005-9007-2. Epub 2006 Mar 7. Ann Biomed Eng. 2006. PMID: 16520902 Review.
Cited by
-
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Front Immunol. 2022 Aug 25;13:953410. doi: 10.3389/fimmu.2022.953410. eCollection 2022. Front Immunol. 2022. PMID: 36091031 Free PMC article. Review.
-
A potential therapeutic strategy for malignant mesothelioma with gene medicine.Biomed Res Int. 2013;2013:572609. doi: 10.1155/2013/572609. Epub 2013 Jan 16. Biomed Res Int. 2013. PMID: 23484132 Free PMC article. Review.
-
Regulatory T Cells Induce Metastasis by Increasing Tgf-β and Enhancing the Epithelial–Mesenchymal Transition.Cells. 2019 Nov 4;8(11):1387. doi: 10.3390/cells8111387. Cells. 2019. PMID: 31690033 Free PMC article.
-
GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment.Cells. 2021 Oct 20;10(11):2811. doi: 10.3390/cells10112811. Cells. 2021. PMID: 34831034 Free PMC article.
-
Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen.Acta Pharmacol Sin. 2019 Apr;40(4):539-545. doi: 10.1038/s41401-018-0038-2. Epub 2018 Jun 19. Acta Pharmacol Sin. 2019. PMID: 29921887 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical